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Abstract Sequential endoproteolytic cleavages operated
by the c-secretase and the b-secretase (BACE1) on the
b-amyloid precursor protein result in the production of the
b-amyloid (Ab) species, with two C-terminal variants, at
residue 40 or at residue 42. Accumulation in brain tissue of
aggregates of Ab42 is the major pathogenetic event in
Alzheimer’s disease (AD). The causes of Ab accumulation
in the common sporadic form of AD are not completely
understood, but they are likely to include oxidative stress
(OS). Data reviewed here shed light on how Ab generation,
oxidative stress, and secretase functions are intimately
related in sporadic AD. According to our hypothesis, in
sporadic AD, OS resulted from several cellular insults such
as aging, hypoxia, hyperglycemia, and hypercholesterol-
emia—that are well-known risk factors for AD develop-
ment—can determine a primary induction of c-secretase
and BACE1. The loop proceeds with the generation of
Ab42 and its signaling to BACE1 transcription.
Keywords Alzheimer’s disease  BACE1 
Oxidative stress  b-amyloid
Introduction
Alzheimer’s disease (AD) is the most common age-related
disease (Bachman et al. 1993); therefore, the risk of AD
increases dramatically in individuals above the age of 70
and it is predicted that the incidence of the disease could
increase a further 3-fold over the next 50 years. AD can be
classified in two forms: sporadic AD, which accounts for
the majority of cases, and a rare familial early onset form
(FAD), in which gene mutations have been observed.
The b-amyloid peptide (Ab) is generated following the
sequential cleavage of its precursor, the b-amyloid pre-
cursor protein (AbPP). AbPP is an integral membrane
protein with a single membrane spanning domain, a large,
extracellular, N-terminus and a shorter, cytoplasmic,
C-terminus. The amyloidogenic processing of AbPP
involves two sequential cleavages operated by the b- and
the c-secretases at the N-and C-termini of Ab sequence,
respectively. The b-secretase (BACE1) cleaves AbPP at
the beginning of the Ab sequence, generating an extra-
cellular soluble fragment, called sbAPP, and an intracel-
lular C-terminal named C99. The last fragment is further
cleaved by the c-secretase that produces Ab peptides of
different lengths, these being predominantly Ab40 and
Ab42.
The central role of Ab in the pathogenesis of AD is
supported by several lines of evidence. Aggregates of Ab
are neurotoxic and initiate a series of events, including the
hyperphosphorylation of tau, which results in neuronal cell
dysfunction and death (Yankner 1996); moreover, Ab
soluble oligomers have been found to alter memory func-
tion in different murine AD models (Dodart et al. 2002;
Lesne´ et al. 2006). All genes bearing mutations that cause
FAD, APP, and presenilins 1 and 2, which represent the
catalytic core of the c-secretase, mediate the accumulation
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of Ab42, increasing its production and accumulation
(Citron et al. 1992; Citron et al. 1997; Lemere et al.1996).
One of the most well-known and studied effects of Ab is
its capacity to induce, and be induced by, oxidative stress
(OS); thus, Ab induces OS in vivo and in vitro (Hensley
et al. 1994; Mark et al. 1997; Murakami et al. 2005; Tabner
et al. 2005) and OS is itself able to induce the increased
production of Ab (Paola et al. 2000; Tamagno et al. 2002;
Tong et al. 2005).
The cause of modified AbPP processing and Ab42
accumulation in sporadic AD is unclear but is likely to
include OS.
OS increase is believed to be an early event in AD
(Nunomura et al. 2001; Cutler et al. 2004) as also con-
firmed by the extensive oxidative damage observed in
mild cognitive impairment (MCI), considered a transition
stage between normal aging and dementia (Lovell and
Markesbery 2001).
Moreover, the identification of oxidatively membrane
damage, cytoskeleton derangement and, consequently, cell
death (Perry et al. 2000) suggest that OS plays an important
role in AD pathogenesis.
Our studies strengthen the hypothesis that OS may also
be a basic common pathway of Ab accumulation, common
to different AD risk factors, such as aging, hypoxia,
hyperglycemia, and hypercholesterolemia.
Oxidative Stress in AD
Of note, the major non-genetic risk factor involved in the
pathogenesis of sporadic late onset AD is aging, which is
strictly related to the damage resulting from reactive oxy-
gen species (ROS) indicative of OS (Markesbery and
Carney 1999).
ROS are a by-products of cellular metabolism and are
generated during mitochondrial oxidative phosphorylation
as molecules with unpaired electrons such as superoxide
(O2
-).
The brain is particularly vulnerable to OS because of its
high consumption of oxygen, high levels of polyunsatu-
rated fatty acids, and relatively low levels of antioxidants
(Floyd and Hensley 2002). Accumulation of oxidative
damage in the brain is particularly dangerous since it is a
post-mitotic tissue with neurons exhibiting only a weak
self-renewal potential due to their low proliferative
capacity.
An increased oxidative burden has been observed in the
brain of non-demented elderly and of sporadic AD patients
(Behl and Moosmann 2002; Moosmann and Behl 2002).
The free radical hypothesis of aging implies the accu-
mulation of ROS resulting in the damage of the major cell
components: nucleus, mitochondrial DNA, membranes,
and cytoplasmic proteins (Harman 1992).
Membrane lipids are commonly attacked by ROS, and
lipid peroxidation is the most frequently oxidative marker
that appears to increase during aging (Zhu et al. 2006). The
oxidative modification of membrane fatty acids leads to a
structural damage and to the generation of aldehydic end
products, such as 4-hydroxynonenal (HNE), which have a
high oxidative potential themselves and can impair cellular
functions (Keller and Mattson 1998).
Post-mortem analysis of the brains of AD subjects found
increased levels of lipid peroxidation in brain regions that
are affected by an early neurodegeneration (Mielke and
Lyketsos 2006).
Several studies show that also protein oxidation
increases with the aging of the brain (Abd El Mohsen et al.
2005) as well as the levels of oxidized proteins in AD
patients and this increase strongly correlate with cognitive
performance (Keller et al. 2005).
Another well-known age-dependent modification medi-
ated by OS is the DNA oxidative damage. It is well known
that mutations in mitochondrial DNA cause a respiratory
chain dysfunction that leads to an increase in ROS pro-
duction. These mitochondrial mutations accumulate during
brain aging and neurodegenerative disorders (Corral-
Debrinski et al. 1992; Wang et al. 2005).
OS increases with age not only through variations in
ROS generation but also in their elimination (Barja 2004).
Indirect evidence of cellular OS is the increased expression
of molecules involved in oxidant defense, such as heme
oxygenase, superoxide dismutases, glutathione transfer-
ases, and catalase (Markesbery and Carney 1999); then
these neurons do not necessarily succumb to OS, but
dynamically regulate their defense mechanisms in response
to oxidants.
In the case of neurodegenerative disorders where OS is
postulated to play a role, the normal balance between
production of and defense against OS has been modified
and OS impairs the cellular defences causing a vicious
cycle.
These challenges become clear during the AD process,
and include a strong presence of increased sulfhydryls,
induction of heme oxygenase-1 and increased expression of
Cu/Zn superoxide dismutase (Nunomura et al. 1999; Smith
et al. 1995; Pappolla et al. 1992), which indicates loss of
homeostasis. Moreover, the protein oxidation that
increases during aging is strictly associated with the
decreased capacity of antioxidant defence machinery
(Rodrigues Siqueira et al. 2005).
OS may be an early event in the progression from nor-
mal aging to AD pathology. Thus, extensive oxidative
damage it has been shown in MCI, a transition stage
between normal aging and dementia.
It has been shown that in MCI subjects, plasma levels of
non-enzymatic antioxidants and activity of antioxidant
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enzymes appeared to be decreased if compared to those of
normal aging subjects (Guidi et al. 2006; Sultana et al.
2009). Moreover, levels of oxidative markers appeared to
be increased.
Proteomic analysis demonstrated a large number of
protein-bound HNE in MCI brain (Song et al. 2009).
F2-isoprostanes (F2-IsoPs) levels and neuroprostanes were
also significantly increased in MCI patients and in late-
stage AD (Markesbery et al. 2005). Moreover, in
brains from patients with MCI, acrolein has been found to
be elevated in hippocampus and temporal cortex where OS
is high. Due to its high reactivity, acrolein is not only a
marker of lipid peroxidation but also an initiator of OS by
adducting cellular nucleophilic groups found in proteins,
lipids, and nucleic acids (Singh et al. 2010). Thus, exten-
sive oxidative damage observed in MCI brain regions
suggests that OS may be an early event in progression from
normal aging to AD.
Based on these notions, it seems likely that increased
production of ROS may act as important mediators of
synaptic loss and eventually promote neurofibrillary tan-
gles and senile plaques formation (Kern and Behl 2009).
In summary, the oxidative burden observed in healthy
brain aging and in early stages of dementia confirms that
the accumulation of oxidatively modified biomolecules is a
general hallmark of brain aging and could be an early event
in the progression of AD.
Oxidative Stress and Major AD Risk Factors
Our studies, as described below, strengthen the hypothesis
that OS may be considered a basic common pathway of AD
progression, common to most important AD risk factors.
Hypoxia
It is well known that patients with stroke and cerebral
infarction are at risk of AD (Rocchi et al. 2009).
Recent studies have shown that a history of stroke can
increase AD prevalence by approximately 2-fold in elderly
patients (Schneider et al. 2003; Vermeer et al. 2003). The
risk is higher when stroke is concomitant with atheroscle-
rotic vascular risk factor (Jellinger 2002).
Recently it has been proposed that hypoxia can alter
APP processing, increasing the activity of the b- and the
c-secretases, resulting in the acceleration of Ab production
and plaques formation in vivo and in vitro (Sun et al. 2006;
Zhang et al. 2007).
We recently showed, both in vivo and in vitro, that
hypoxia up-regulates BACE1 expression in a biphasic
manner, through two distinct mechanisms: (a) an early
release of ROS from mitochondria and (b) a late activation
of HIF-1a, a molecule that regulates oxygen homeostasis
(Guglielmotto et al. 2009). The data suggest that the early
post-hypoxic up-regulation of BACE1 depends on the
generation of ROS mediated by sudden interruption of the
mitochondrial electron transport chain. Although it is
generally accepted that intracellular ROS levels change
during hypoxia, the direction in which this change occurs is
still debated. Many Authors reported that the level of
intracellular ROS increases under hypoxia and suggested
that mitochondria are the source of ROS involved in this
cellular response (Chandel et al. 1998; Turrens 2003;
Klimova and Chandel 2008). It is now accepted that
hypoxia increases ROS via the mitochondrial transport
chain and specifically by the function of complex III (Bell
et al. 2007).
Hyperglycemia
Diabetes mellitus, a metabolic disorder characterized by
hyperglycemia, is an important risk factor for AD, and
multiple mechanisms connecting the two diseases have
been proposed.
Hyperglycemia enhances the formation of advanced
glycation end-products (AGEs) senescent protein deriva-
tives that result from the auto-oxidation of glucose and
fructose (Bucala and Cerami 1992; Brownlee et al. 1988;
Takeuchi and Makita 2001).
The involvement of AGEs in brain aging and AD was
reported many years ago in studies showing that the
microtubule associated protein tau and Ab were substrates
of glycation (Ledesma et al. 1994; Smith et al. 1994; Vitek
et al. 1994; Yan et al. 1994; Yan et al. 1995).
More recently it has been reported that AGEs have other
pathological effects at cellular and molecular levels.
Among these are the production of ROS, especially
superoxide and hydrogen peroxide (Carubelli et al. 1995;
Muscat et al. 2007). Moreover, glycated proteins increase
the rate of free radical production compared to native
proteins (Neeper et al. 1992).
Another mechanism through which AGEs mediate the
production of OS is the interaction with RAGE, which is a
multiligand receptor of the immunoglobulin superfamily of
cell surface molecules (Qin et al. 2008). The role of RAGE
in the pathogenesis of AD has been extensively studied
because it also binds Ab (Yan et al. 1996).
We recently demonstrated a novel pathogenic mecha-
nism of AGEs, which contributes to Ab accumulation
(Guglielmotto et al. 2010). In streptozotocin rats, as well as
in SK-N-BE differentiated neuroblastoma cells, two dif-
ferent AGEs, pentosidine and glyceraldehyde derived
pyridinium (GLAP), were able to up-regulate BACE1
expression through their binding with RAGE which is
followed by a strong production of ROS and by an acti-
vation of the NF-jB pathway, which is a representative
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transcription factor activated by RAGE (Granic et al.
2009). Moreover, NF-jB has been recently identified as a
molecular intermediate involved in the Ab-mediated con-
trol of BACE1. Thus, the inhibitor of IjB kinase that
blocks NF-jB transcriptional activity fully reverses the
Ab42-induced increase of BACE1 promoter transactivation
(Buggia-Prevot et al. 2008). These data agree with a pre-
vious report showing that BACE1 promoter transactivation
could be regulated by NF-jB in neuronal cells (Bourne
et al. 2007).
The role of RAGE on BACE1 up-regulation was
reported before in RAGE-injected brains of AD animal
model and in cultured cells (Cho et al. 2009). Our results
confirmed and extended this finding by showing that nat-
ural ligands of RAGE, AGEs, mediate BACE1 up-regula-
tion in a diabetic animal model as well as in culture model.
Thus, activation of AGEs/RAGE axis, as a result of
hyperglycemia, driving the up-regulation of the key
enzyme for Ab production, provides a mechanistic link
between diabetes mellitus and AD.
Hypercholesterolemia
Recent studies indicate that alterations in cholesterol
metabolism influence some molecular mechanisms
involved in AD. Three important lines of evidence have
implicated cholesterol in AD; (a) hypercholesterolemia is
recognized to be a risk factor for sporadic AD (Puglielli
et al. 2003; Panza et al. 2007); (b) epidemiological studies
showed that APO-E4 allele is strictly associated with an
increased risk of AD (Corder et al. 1993; Evans et al.
2004); (c) feeding cholesterol to rabbits produces some of
the pathological hallmarks of AD, including amyloid pla-
ques (Kandiah and Feldman 2009).
Moreover, early epidemiological studies indicated that
cholesterol-lowering drugs, belonging to the family of
statins, reduce the prevalence of AD (Jick et al. 2000), a
conclusion not fully accepted because of other contradic-
tory clinical studies (Kandiah and Feldman 2009; Ishii
et al. 2003; Serrano-Pozo et al. 2010).
Thus, if altered cholesterol metabolism in the brain has
repeatedly been suggested to be implicated in the patho-
genesis of AD, the molecular mechanisms underlying its
involvement are still largely unknown.
Cholesterol is essential for normal brain functions; most
of it is present in the free form and derives from de novo
synthesis by astrocytes, as plasma lipoproteins cannot cross
the blood–brain barrier (Puglielli et al. 2003), but choles-
terol can only be transformed in oxysterols, cholesterol
oxidation products that are important to balance the local
synthesis of sterols (Lu¨tjohann et al. 1996). We suggested
that oxysterols might represent a link between altered
cholesterol metabolism in the brain and AD (Gamba et al.
2011). Thus, we recently demonstrated an enhancement of
Ab binding to neuronal cells exerted by oxysterols relevant
in brain physiology such as 27-OH cholesterol, 24-OH
cholesterol, and 7b-OH cholesterol. The increase has been
related to the strongly oxysterols-mediated up-regulation of
CD36 and b1 integrin, a well characterized multireceptor
complex, able to stimulate the Ab binding to neuronal
cells.
We have also recently demonstrated an up-regulation of
BACE1 mediated by the sterol regulatory element binding
protein 2 (SREBP2) transcription factor, that tightly reg-
ulates the brain cholesterol metabolism, in rats fed with a
high fat diet mimicking cholesterol-rich western diet as
well as in differentiated SK-N-BE neuroblastoma cells
exposed to high cholesterol levels (Mastrocola et al.
2011).
Since it is well known that BACE1 activity located in
cholesterol-rich rafts may be positively modulated by
cholesterol levels (Cordy et al. 2003; Wolozin 2004), our
data on the direct regulation of BACE1 by SREBP2 tran-
scriptional activity adds new insights on the complex
molecular mechanisms underlying the implication of cho-
lesterol in the pathogenesis of AD.
The data here reported strongly supported the hypothesis
that OS could be a basic common pathway of Ab accu-
mulation, as determined by different age-related risk fac-
tors (Fig. 1).
Ab Production is a Major Link Between Oxidative
Stress and Pathogenesis of AD
According to the amyloid cascade hypothesis of AD, Ab is
considered to be the primary motor of neuronal degenera-
tion, although the pathway leading to neuronal death is
extremely complicated (Hardy and Allsop 1991).
It is still controversial whether the most deleterious form
of Ab peptides in the early stage of AD is represented by
the fibrillar or the soluble oligomeric peptide form (Drouet
et al. 2000).
Although neuronal degeneration occurs in proximity of
the amyloid plaques, some studies have suggested that
intermediate Ab aggregates such as protofibrils or simple
oligomers are also involved in AD pathogenesis and even
appear to be the most dangerous species (Gong et al. 2003;
Kayed et al. 2003; Resende et al. 2008; Tamagno et al.
2006). These data may help to explain, for example, why
neurodegeneration and specific spatial learning deficits
may occur in AD animal models before the appearance of
amyloid plaques (Chui et al. 1999; Koistinaho et al. 2001).
More attention has thus been focused on the early stages
of amyloid production and on its maturation from small
soluble molecules to oligomers and fibrils with high
molecular weight.
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One of the most known and studied effects of Ab is its
ability to induce, and be induced by, OS. Several
by-products of protein, lipid, and glucose oxidation seem to
be elevated in the brain of patients with AD and to a lesser
extent in the brains of healthy aged controls, as the burden
of free radicals builds up proportionally to the duration of
the disease (Borghi et al. 2007; Butterfield et al. 2001;
Markesbery and Lovell 1998; Sayre et al. 1997). Both
amyloid deposits and soluble Ab seem to drive the accu-
mulation of ROS (Behl 2005; Pratico` 2008).
Transition metals, Cu(II), Zn(II), and mainly Fe(III)
favor the neurotoxicity of Ab, through their reduction, that
yields hydrogen peroxide (H2O2) (Huang et al. 1999). It
has been shown that Ab residue Tyr-10 is a pivotal residue
in driving the catalytic production of H2O2 in the presence
of Cu(II). The phenoxy radical of this residue produced by
the reaction with ROS causes neurotoxicity and accelera-
tion in Ab peptides aggregation (Barnham et al. 2004).
Another crucial residue of Ab is Met-35, thus the sub-
stitution of Met with cysteine resulted in no protein oxi-
dation in C. Elegans model (Yatin et al. 1999). An
interesting downstream effect of Ab-induced OS on lipids
is the interference with membrane stability and the gen-
eration of calcium flow into the cells, leading to enhanced
toxicity (Kirkitadze and Kowalska 2005). Moreover, lipid
peroxidation induced by Ab peptides impairs the function
of ion-motive ATPase, glucose, and glutamate transporters
and of GTP- binding protein, as the results of their covalent
modification by aldehydic end products such as HNE.
Ab is also able to induce oxidative modifications of
proteins involved in cellular defence mechanisms against
noxious stimuli as well as in energy pathways. In a murine
experimental knock-in model of AD, harboring APP and
PS1 mutations, a direct correlation between the excessive
production of Ab peptides and impairment of antioxidant
enzymes, with consequent mitochondrial dysfunction, was
reported (Anantharaman et al. 2006). These are further
demonstrations of how increased OS induced by Ab can
lead to increased oxidative modifications of proteins and
lipids leading to impaired cellular functions and cell death,
and consequently cognitive impairment and AD pathology
(Sultana et al. 2009).
Furthermore, Ab can strike the production of pro-
inflammatory mediators, such as TNF-a or IL-1b, leading
to microglia activation, OS induction, and enhanced pro-
cessing of APP to generate more Ab (Akiyama et al. 2000;
Atwood et al. 2003). In this connection, of particular
interest is the report that APP promoter responds positively
to inflammatory mediators; the inflammatory response
leads to enhanced APP and Ab productions and the
involvement of OS is suggested by the finding that the iron
chelation is able to reverse the phenomenon (Rogers et al.
2002).
OS may also be the cause of Ab accumulation. Oxidant
agents and oxidative products increase APP expression
(Cheng and Trombetta 2004; Patil et al. 2006) and intra-
cellular and secreted Ab levels in many neuronal and non-
neuronal cellular types (Frederikse et al. 1996; Misonou
et al. 2000; Atwood et al. 2003; Murray et al. 2007).
We have extensively analyzed the transcriptional acti-
vation of BACE1, the key enzyme for Ab production, first
in response to OS, both in vivo and in vitro.
BACE1 gene promoter has a complex structure, carrying
several transcription factor binding sites, such as for SP1,
AP1, AP2, CREB, glucocorticoid receptor, NF-jB, and
others (Sambamurti et al. 2004).
Different signaling pathways, such as SP1 (Christensen
et al. 2004), JNK/AP1 (Tamagno et al. 2008), NF-jB
(Buggia-Prevot et al. 2008), and p25/cdk5/STAT3 (Wen
et al. 2008) have been suggested to control BACE1
transcription.
We and others have shown that the expression
and activity of BACE1 is increased by oxidant agents
(Tamagno et al. 2002; Tamagno et al. 2003; Tamagno et al.
2005; Kao et al. 2004; Tong et al. 2005). Several reports
show that levels of BACE1 protein and activity are
increased in brain of sporadic AD patients, compared to
Hypoxia
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ROS
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A
HIF-1 NF- B
JNK/AP-1
Fig. 1 Diagram sketching of the hypothesis that OS could be a basic
common pathway of Ab accumulation, as determined by different
age-related risk factors
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normal age controls (Fukumoto et al. 2002; Holsinger et al.
2002; Yang et al. 2003; Zhao et al. 2007); moreover, there
is a significant correlation of BACE1 activity and oxidative
markers in sporadic AD tissues (Borghi et al. 2007).
We have proposed a sequence of events that link OS,
BACE1 induction, and apoptotic cell death mediated by an
overproduction of Ab. First, we have shown that oxidant
agents and HNE significantly increase the expression,
protein levels, and activity of BACE1 in NT2 neurons
(Tamagno et al. 2002; Tamagno et al. 2003). These events
are followed by both an overproduction of Ab peptides and
morphological signs of apoptotic cell death (Tamagno et al.
2005).
Then we have found that OS increases the c-secretase
activity in cultured cells and in vivo, and that the increased
expression of BACE1 induced by OS is regulated by the
c-secretase activity (Tamagno et al. 2008). These results
have important implications for the pathogenesis of spo-
radic AD. First, they suggest that OS, secondary to dif-
ferent AD risk factors, can increase the expression of both
secretases, thereby enhancing Ab production. Second, our
data revealed the existence of a positive feedback loop in
which c-secretase activity results in up-regulation of
BACE1 expression. Previously Minopoli et al. (2007) had
shown a correlation between the induction of OS and the
increase of c-secretase cleavage on APP and then Jo et al.
(2010) confirmed the finding that c-secretase up-regulates
BACE1 expression.
An increasing body of evidence implicates brain
inflammation related to OS in the up-regulation of BACE1.
Thus, the BACE 1 promoter has also a binding site for the
transcriptional regulator proliferator-activated receptor c
(PPAR c) (Sastre et al. 2006). Activation of PPARc by non-
steroidal anti-inflammatory drugs (NSAIDs) or PPARc
agonists cause repression of BACE1 gene promoter activ-
ity, while pro-inflammatory cytokines that reduces PPARc
levels lead to increased BACE1 mRNA (Sastre et al. 2006).
Several different mechanisms appear to be involved in
the OS-mediated BACE1 up-regulation, and probably they
overlap to promote the activation observed.
Our data strongly suggest that OS contributes to the
pathogenesis of the common, sporadic, late-onset form of
AD, and that, being able to up-regulate c-secretase and
BACE1, can be the molecular link between the two
secretases.
These findings led us to think that either Ab peptides or
the APP intracellular domain (AICD) could be the APP
derivatives from the c-secretase cleavage responsible for
BACE1 induction.
We investigated which derivative was responsible for
BACE1 up-regulation. We first analyzed the effect of the
AICD fragments 57 ad 59, the APP derivatives resulting
from the c-secretase cleavage of APP, as well as AICD 50
and 51 that are the e cleavage derivatives (Passer et al.
2000; Tagami et al. 2008; Fukumori et al. 2006).
Transfection of different cell lines with the corresponding
AICD constructs determined no change in BACE1 expres-
sion, thus our experiments ruled out the role of AICD in the
over-expression of BACE1 and pointed to Ab peptides
(Giliberto et al. 2009). Thus, it is well known that mutant PS1
determines a drastic increase of Ab42 species (Duff et al.
1996) and familial AD cases with PS1 mutations have mostly
an increased ratio of Ab42/40. We found that over-expres-
sion of PS1 mutants could alone determine an increase of
BACE1 expression (Giliberto et al. 2009).
Instead, treating neuronal and neuroblastoma cells with
1 lM soluble Ab42 increased BACE1 transcription, which
was reverted if anti Ab42 antibody was added to culture
medium (Giliberto et al. 2009). Of note, Ab40 has much
less effect on BACE1 expression (Guglielmotto et al.
2011).
These findings reveal a novel function of Ab peptides
showing that Ab42 is the player of a positive feedback loop
from the c-secretase cleavage on the BACE1 cleavage of
APP (Fig. 2).
BACE1
OXIDATIVE STRESS
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A PP
C99
A 42
Receptors:
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TrkA
p75NTR
NMDA
othersendosomes
- secretase
A 42
pJNK 
A PP
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BACE1
mRNA
nucleus
pJNK 
AP1 others?
Fig. 2 Pathogenetic hypothesis in which OS fosters the expression
and activity of BACE1 through the release of Ab42 peptides and the
activation of JNK/AP-1 pathway
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It is not clear how Ab42 could reach BACE1 tran-
scription apparatus. There are many signaling pathways
that seem to be regulated or at least affected by Ab pep-
tides. Among these Buggia-Prevot et al. (2008) found that
Ab42 was able to modulate BACE1 promoter transacti-
vation and activity through an NF-jB-dependent pathway.
Thus, an IkappaB kinase inhibitor prevents Ab42-
induced BACE1 promoter transactivation suggesting that
NFkappaB could mediate this Ab42-associated phenotype
(Buggia-Prevot et al. 2008).
We recently found that also JNK/cjun pathway activa-
tion may be involved in the BACE1 up-regulation medi-
ated by Ab42 (Guglielmotto et al. 2011).
This pathway links all the pathological hallmarks of AD.
JNK activation has been reported to regulate the phos-
phorylation of APP, leading to modulation of Ab levels
(Colombo et al. 2007; Colombo et al. 2009), as well as to
mediate the phosphorylation of tau protein in vitro
(Yoshida et al. 2004). Furthermore, the JNK pathway is
shown activated in preclinical models of AD, including
Tg2576 and Tg575/PS1P264L transgenic mice (Flood et al.
2002; Puig et al. 2004), as well as in brains of AD patients
(Zhu et al. 2003a; Zhu et al. 2003b; Lagalwar et al. 2006).
Indeed, we had previously found a significant activation
of JNK/AP1 pathway by OS both in vivo and in vitro
models, and the up-regulation of BACE1 was abolished
when the pathway had been genetically or pharmacologi-
cally inhibited (Tamagno et al. 2008).
It remains to be determined how Ab42 activates JNK
pathway. Ab is known to alter intracellular calcium hos-
meostasis (Demuro et al. 2010), and JNK could be acti-
vated by the calcium/calmodulin dependent protein kinase
II (CAMKII) (Wu et al. 2009) or by a PI3K inducing
signal, mediated by calcium release (Assefa et al. 1999).
Furthermore, it has been observed that Ab-induced
increase in intracellular calcium concentration stimulates
BACE1 expression, resulting in accelerated Ab generation,
and that this process is mediated by the calcineurin-NFAT1
signaling pathway. NFAT1 is normally dephosphorylated
by calcium-dependent manner by calcineurin, while it is
phosphorylated and inactivated by JNK (Cho et al. 2008).
Results of Ortega-Perez et al. (2005), however, demon-
strated that, unlike other NFAT members, the transcrip-
tional activity of NFATc2 appears up-regulated by JNK.
Based on these notions, JNK-mediated phosphorylation of
NFATs could play a differential physiological role among
NFAT family members.
Cell surface receptors may be involved as well.
Numerous proteins have been described to interact with Ab
directly or indirectly, such as AbPP itself, TrkA, p75NTR,
some G proteins, NMDA, and AMPA receptors and many
more. Thereby, the interaction of Ab42 with multiple
receptors is likely to produce the activation of the JNK/
c-jun pathway. AbPP has been shown to function as a cell
surface receptor that mediates neuronal cell death through
the activation of JNK pathway (Hashimoto et al. 2003).
Moreover, JNK pathway is shown involved in Ab-driven
signaling, as downstream of Ab-RAGE interaction (Yan
et al. 1996), TrKA/p75NTR (Yaar et al. 2007; Costantini
et al. 2005), NMDA, and AMPA receptors (Di et al. 2010;
Vieira et al. 2010). In general, the JNK signaling seems
activated in AD (Lagalwar et al. 2006) and strongly cor-
relates with the OS in AD models (Tamagno et al. 2005).
Also, besides being a means of scavenging Ab from
tissues and having a role in modulating APP endocytic
trafficking, LRP family receptors and apolipoprotein E, of
which the e4 allele has a strong linkage with AD, could
represent a way for Ab to enter into neuronal cells (Bu
et al. 2006; Jaeger and Pietrzik 2008) and interact with
other still unidentified molecules to strike the signaling
pathway that leads to BACE1 regulation.
Thus, the effects of Ab on the cell are extremely com-
plex. Being able to understand the specific signaling and to
understand how soluble or insoluble Ab induces its own
production by up-regulating BACE1 expression would lead
to new tools to interrupt the vicious circle, with potential
therapeutics consequences.
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